Skip to Content

News Releases

Jun 13 2022
SomaLogic Announces License Agreement with OncoHost for the Development of Precision Cancer Diagnostics
BOULDER, Colo. and BINYAMINA, Israel, June 13, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced it has signed a licensing agreement with OncoHost, a global leader in next-generation precision oncology for personalized cancer therapy.
Jun 01 2022
SomaLogic Announces June Conference Participation
BOULDER, Colo., June 01, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the following conferences. Jefferies Healthcare Conference June 8-9, 2022, in New York 7th Annual MarketsandMarkets
May 12 2022
SomaLogic Reports First Quarter 2022 Financial Results
Company to host conference call today at 4:30 p.m. ET BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended March 31, 2022. “Our successful first quarter has kickstarted another
Apr 21 2022
SomaLogic to Announce First Quarter 2022 Financial Results
BOULDER, Colo., April 21, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. Company management will host a corresponding
Apr 12 2022
Major journal publishes landmark proteomics study demonstrating development of an unprecedented new clinical cardiovascular risk test
SomaScan® platform study utilizing 32,000 samples showed a 27-protein test is a uniquely superior surrogate for cardiovascular outcomes BOULDER, Colo., April 12, 2022 (GLOBE NEWSWIRE) -- In one of the largest proteomic studies ever conducted and published April 6 in the journal Science
Mar 29 2022
SomaLogic Reports Fourth Quarter and Full Year 2021 Financial Results
Fourth quarter 2021 revenue of $23.0 million contributed to record full year revenue of $81.6 million, 46% growth over the prior year Established over 75 new customer accounts, expanding and diversifying revenue base Substantial cash and investments of $657.7 million at year-end Maintaining 2022
Mar 21 2022
SomaLogic to provide 210 million protein measurements to EPIC researchers to better understand and predict cancer development
BOULDER, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will begin assaying samples from the European Prospective Investigation into Cancer and Nutrition (EPIC) study beginning in the first quarter
Mar 01 2022
SomaLogic to Announce Fourth Quarter and Full Year 2021 Financial Results
BOULDER, Colo., March 01, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 29, 2022.
Feb 25 2022
SomaLogic to Participate in the Cowen 42nd Annual Health Care Conference
BOULDER, Colo., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the Cowen 42nd Annual Health Care Conference. SomaLogic management is scheduled to participate in a fireside chat on
Feb 04 2022
SomaLogic Provides 2022 Revenue Guidance in Conjunction with Analyst and Investor Meeting
BOULDER, Colo., Feb. 04, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual analyst and investor meeting today, February 4 th , 2022, from 10:00 a.m. to approximately 1:00 p.m. Eastern Time.
Displaying 1 - 10 of 16